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The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases 
predisposes to the development of inflammatory bowel disease-associated colorectal cancer (IBD-
CRC). Inflammation can induce mutagenesis and the relapsing-remitting nature of this inflammation, 
together with epithelial regeneration, may exert selective pressure accelerating carcinogenesis. The 
molecular pathogenesis of IBD-CRC, termed the ‘inflammation-dysplasia-carcinoma’ sequence, is 
well described. However, the immunopathogenesis of IBD-CRC is less well understood. The impact of 
novel immunosuppressive therapies, which aim to achieve deep remission, is mostly unknown. 
Therefore, this timely review summarises the clinical context of IBD-CRC, outlines the molecular and 
immunological basis of disease pathogenesis and considers the impact of novel biologic therapies. 
 





















Inflammatory bowel disease (IBD) describes chronic immune-mediated conditions 
characterised by relapsing-remitting inflammation of the gastrointestinal tract. Ulcerative colitis (UC) 
and Crohn’s disease (CD) are the dominant phenotypes and prevalence is estimated to be as high as 
1 in 125 (0.8%) in countries such as the UK.1 While prevalence is rising throughout the world, the 
greatest acceleration is observed in newly industrialised countries: since 1990 Africa, Asia and South 
America have seen an annual percentage change of +11.1% (95%CI 4.8, 17.8) for CD and +14.9% 
(95%CI 10.4, 19.6) for UC.2 With an ageing population compound prevalence suggests that IBD-
associated colorectal cancer (herein IBD-CRC) could become an emerging global issue. 
Over the past two decades, we have defined IBD-CRC through the inflammation-dysplasia-
carcinoma sequence (Figure 1). However, many fundamental questions remain, including elucidation 
of disease immunopathogenesis. The impact of potent immunosuppressive therapies in IBD, which 
aim to achieve ‘deep remission’, is mostly unknown and their subsequent effect on IBD-CRC is yet to 
be established. This timely review summarises the epidemiological and clinical context of IBD-CRC, 
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PATIENTS WITH IBD ARE AT INCREASED RISK FOR DEVELOPING CRC WITH A POOR PROGNOSIS 
A 2012 meta-analysis of population-based cohort studies (n=10385 patients) reported that 
patients with UC have an increased risk of developing CRC (SIR 2.4, 95% CI 2.1, 2.7), especially if they 
are male, have extensive colitis and are young when diagnosed with UC.3 A more recent study by 
Olén and colleagues (n=96447 UC and n=949207 control patients) reported that, while the incidence 
of UC-CRC may be decreasing in Scandinavian countries, patients with UC have a 1.7-fold increased 
risk for incident CRC compared with matched controls.4 
For CD, Canavan and colleagues published a meta-analysis (n=11840 patients) that reported 
the relative risk for developing CRC in those with colonic disease is 4.5 (95% CI 1.3, 14.9), with a 
cumulative risk of 2.9% (95% CI 1.5, 5.3) 10 years after diagnosis.5 A prospective cohort study from 
Hong Kong (n=2621 patients) reported that patients with CD have an increased risk of anorectal 
cancer (SIR 4.11, 95% CI 1.84, 9.14).6 A more recent study by Olén and colleagues (n=47035 CD and 
n=463187 matched reference individuals) also demonstrated increased CRC incidence in CD: HR 1.40 
(95% CI 1.27, 1.53).7  
There is also an increased IBD-CRC risk for paediatric patients; a 2018 review (n=271 
patients) concluded that, while rare, colorectal cancer is the most common fatal malignancy in 
paediatric IBD patients.8 
IBD-CRC confers a poor prognosis. A large meta-analysis (n=3472 patients) reported that 
patients with IBD-CRC have poorer overall survival compared to patients with sporadic(S)-CRC (HR 
1.24 95% CI 1.19, 1.29).9 These patients were more likely to have proximal tumours (OR 2.52, 95% CI 
1.35, 4.72) and poorer histopathological differentiation (OR 1.59, 95% CI 1.26, 1.99). Olén and 
colleagues also reported patients with UC have a 1·6-fold increased risk of death from cancer, 
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controls (HR 1.42, 95% CI 1.16, 1.75), when adjusted for tumour stage.7 Reported differences 
between IBD-CRC and S-CRC prognosis are likely due to differences in tumour biology (Table 1).10  
 
IBD-CRC DEVELOPS FROM DYSPLASIA AND INFLAMMATION IS A CRITICAL INITIATING FACTOR 
With an increasing global prevalence of IBD, and patients living longer, it is important to 
consider the cumulative impact that multiple occurrences of acute and chronic inflammation have 
on the development of IBD-CRC. Clinicians strive to modulate natural disease progression at a very 
early stage, often using potent agents to achieve early mucosal healing. The ‘top down’ or ‘treat to 
target’ approach aims to reduce the risk of hospitalisations, future biologic use and surgery. While 
lower colectomy rates are desirable, preservation of damaged colorectum, particularly in the setting 
of potent immunomodulation, is unknown and could result in increased incidence of IBD-CRC. 
Understanding the molecular and immunological pathogenesis of IBD-CRC is therefore important for 
clinicians and scientists to develop new therapies that achieve deep remission and reduce IBD-CRC 
risk. 
Our current understanding of S-CRC is defined through the sequential histological and 
genetic changes known as the adenoma-carcinoma sequence (Figure 2A). In contrast, IBD-CRC 
develops through the ‘inflammation-dysplasia-carcinoma’ sequence (Figure 2B). Here, low-grade 
dysplasia develops on a background of mucosa that has been genetically altered by chronic 
inflammation and is at increased risk of malignant progression. Inflammation can induce mutations 
and the relapsing-remitting nature of this inflammation with proliferative epithelial regeneration 
exerts selective pressure that accelerates evolution.11 Increased reactive oxygen species production 
and lipid peroxidation and decreased antioxidant capacity with increased oxidative DNA damage in 
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Mutations that contribute to IBD-CRC pathogenesis are similar to those implicated in S-CRC; 
however, the order that mutations are accrued is often described as ‘reversed’. Early loss of TP53 
function is a hallmark of IBD-CRC, with mutations observed in diploid, non-dysplastic epithelial cells 
and they precede TP53 loss of heterozygosity.14 In contrast, S-CRC TP53 mutations occur late.14 KRAS 
activating mutations are important alternative gatekeeper mutations that occur later and less 
frequently in IBD-CRC (~20% of cases).15 Hypermethylation of tumour suppressor gene MLH1 also 
occurs earlier in IBD-CRC, and this contributes to microsatellite instability (MSI) in an important 
subset of cancers, similar in frequency to that observed in S-CRC.16 Dysregulation of the Wnt 
signalling pathway plays an important role in IBD-CRC, with ~55% of dysplastic lesions and up to 
100% of cancers expressing nuclear β-catenin.17 However, unlike the S-CRC pathway which has early 
loss of APC function leading to aberrant Wnt signalling, APC function is lost late in IBD-CRC and only 
occurs in <50% of cases.15,18 This may be explained by inflammation-driven upregulation of β-catenin 
in IBD-CRC, which can induce APC mutation-independent Wnt signalling.19  
Throughout the IBD colon, genetic and epigenetic abnormalities develop in histologically 
normal mucosa and can expand to form pre-malignant patches.20 IBD patients have dysplastic 
lesions with increased chromosomal instability compared with sporadic adenomas.21 Chronic 
inflammation is the underlying mechanism that leads to telomere shortening, thus chromosomal 
instability,22 in pre-malignant IBD mucosa.23 This induces senescence which acts as a tumour-
suppressor mechanism to prevent progression past low-grade dysplasia. Mutant intestinal epithelial 
cells (IECs) eventually escape senescence and progress – this is associated with telomere lengthening 
and loss of TP53 function.  
The mutational landscape of cancer is diverse; our recent mutational analysis of 34 IBD-CRCs 
identified 6 distinct mutational signatures.24 In S-CRC with MSI, patients have a better prognosis by 
at least 15%, which is likely due to a cumulative mutational burden with resulting anti-tumour 
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with MSI (especially loss of MLH1 and defects in DNA POLE proofreading function), and have a higher 
predicted neo-epitope load,24 suggesting increased immunogenicity. It is unknown if or how chronic 
inflammation in IBD influences the development of IBD-CRC mutational signatures or molecular 
phenotypes. 
 
DYSREGULATION OF CRITICAL IMMUNE-MEDIATED PATHWAYS IN IBD-CRC 
NF-𝛋B and IL-6/STAT3 signalling pathways promote IBD-CRC 
The two most comprehensively studied pro-inflammatory and pro-tumour pathways in IBD-
CRC are nuclear factor kappa-light-chain-enhancer of activated B cells (NF-𝛋B) and interleukin (IL)-
6/signal transducer and activator of transcription (STAT)3 signalling pathways. These pathways are 
well established26–28 (Figure 3). 
In summary, inhibition of the canonical NF-𝛋B pathway abrogates tumorigenesis in the 
azoxymethane (AOM)/dextran sulphate sodium (DSS) mouse model by two main mechanisms: 1) 
IKKβ deletion in myeloid cells reduces both intestinal inflammation and tumour size through 
decreased production of pro-inflammatory cytokines (IL-1ɑ, IL-1β, IL-6, KC, MIP-2, tumour necrosis 
factor (TNF)-ɑ, COX-2 and ICAM), and 2) IKKβ deletion in IECs reduces tumour incidence and is 
associated with apoptosis; however, it does not reduce inflammation.29 Non-canonical NF-𝛋B 
signalling, mediated by NF-𝛋B-inducing kinase signalling (NIK), contributes to intestinal homeostasis 
through maintenance and differentiation of microfold (M)-cells (specialised epithelial cells of 
mucosal-associated lymphoid tissue) and local and systemic IL-17A and IgA production.30 Mice with 
intact NIK are protected against colitis; however, constitutively activated NIK signalling worsens 
colitis and is associated with increased IL-17A production and ectopic colonic M-cells.30 NF-𝛋B 
signalling can also be driven by genetic aberrations: mutant p53 augments and prolongs the 
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promotes persistent tissue damage and inflammation.31 Mutant p53 mice exposed to DSS are prone 
to colitis-associated cancer: the gain-of-function mutation is associated with flat dysplastic lesions 
that progress to cancer, similar to those seen in IBD-CRC.31 
TNF-ɑ is the quintessential pro-inflammatory cytokine and can bind to either of its receptors 
(TNFR1 or TNFR2) and induce inflammation through either canonical or non-canonical NF-𝛋B 
signalling pathways. There are data suggesting TNF-ɑ can enhance Wnt signalling through NF-𝛋B 
actvation32 and promote mucosal regenerative healing through colonic epithelial stem and 
progenitor cell populations.33 A protective role for TNF is perhaps controversial. Nonetheless, this is 
important to consider in IBD-CRC as IEC p53 stabilisation post-immune activation is dependent on 
TNFR1/2 and inducible nitric oxide synthase (iNOS).34 TNF-ɑ-induced iNOS activates a p53-
dependent pathway of IEC apoptosis, and this may hypothetically be prevented in patients receiving 
anti-TNF treatment. This could mean that without p53 wild type function, such as during early IBD-
CRC, damaged IECs evade apoptosis and thus have selective advantage.34  
NF-𝛋B signalling in immune and epithelial cells upregulates IL-6 and constitutively activates 
STAT3 in human tumours, maintaining NF-𝛋B signalling.35 Thus, IL-6/STAT-3 and NF-𝛋B signalling are 
not mutually exclusive. IL-6/STAT3 deficient mice treated with AOM/DSS have a reduced tumour 
burden compared with wild type mice.36,37 This is because IL-6, produced mainly by bone marrow-
derived myeloid cells, such as macrophages and dendritic cells (along with some T-cells), increases 
IEC proliferation and resistance to apoptosis through the STAT3-dependent pathway.36,37 Further, 
STAT3 acts as a critical mediator for stimulating cell survival (bcl-x, survivin, Hspa1a) and 
proliferation (cdk4/cyclinD1, cdc2/cyclinB1, cMyc, RegIIIb/PAP), through G1 and G2/M phases of the 
cell cycle to promote carcinogenesis.37  
Increased IL-6 expression in UC is also associated with reduced nuclear expression of MSH3, 
and this increases with duration of disease, as well as when dysplasia then cancer develops; 
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IBD-CRC. Trans-IL-6 signalling - where IL-6 binds to soluble IL-6R and dimerises with gp130 on cells 
that do not express IL-6R is also important; macrophage-derived IL6/soluble IL6Rɑ is particularly 
important.39,40  
STAT3 signalling can also be induced by other cytokines, such as IL-11, which may be more 
potent.41 STAT3 is important to Th17 cell function as FAM64A, a multifunctional protein involved in 
cell cycle progression, drives the IL-6/STAT signalling pathway and induces Th17 differentiation in 
AOM/DSS-induced murine colitis.42 
 
Th17 cells and associated cytokines promote IBD-CRC 
Patients with IBD have an increased Th17 cells and associated cytokines (IL-17, IL-21 and IL-
22) in their intestinal mucosa and peripheral blood, compared with healthy controls.43 It is important 
to differentiate IL-17A (which promotes inflammation and tumorigenesis) from IL-17F (which is 
protective against IBD-CRC, possibly by inhibiting angiogenesis).44,45 IL-6/STAT3 signalling is also 
involved in the induction of T-cell RORγt expression - a key transcription factor of Th17 cells.46 
However, Th17 cells demonstrate functional plasticity and can convert into interferon (IFN)-γ 
producing Th1 cells or regulatory T-cells.47 
IL-23 is produced by many antigen presenting cells and plays an important role in 
maintaining the Th17 cell phenotype.48 In IBD-CRC, data suggest Baft-dependent IL-23+IL-6+CD4+Th17 
cells, rather than RORγt-dependent Th17 cells, mediate downstream effects of IL-23.49 IL-23 and IL-
12 are part of the IL-12 family of cytokines, both share the p40 subunit, and heterodimerise with p19 
or p35, respectively.50,51 p47phox is a protein of NADPH oxidase that regulates induction of TLR9-
induced IL-12/Th1 axis. In AOM/DSS-treated mice, IL-12p35-/- mice have reduced colitis but 
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growth.52 Therefore, tilting the IL-23/IL-12 balance toward IL-12 might reduce tumourigenesis in IBD-
CRC. However, this is not viable as this would likely worsen IBD symptoms.52 
IL-22 is a pleiotropic cytokine, part of the IL-10 family, that is produced by mature Th17 cells 
through IL-23-mediated STAT3 activation.47 In Rag2-/- mice with Helicobacter-associated colitis, IL-22 
induces iNOS within IECs which induces DNA damage and dysplasia.53 Patients with IBD have 
increased CD4+ T-cells that produce high levels of IL-22 binding protein (IL-22BP): IL-22BP is a soluble 
IL-22 receptor, without a transmembrane/intracellular domain, that binds to and neutralises IL-22. 
The anti-inflammatory effects of TNF-ɑ antibodies have been associated with reduced levels of IL-
22BP.54 IL-22BP is highly expressed in dendritic cells and during NLRP3 or NLRP6 inflammasome 
activation, such as in IBD; inflammasome activation can lead to IL-18-dependent IL-22BP 
downregulation. IL-22BP-/- mice also show strongly accelerated tumour growth.55 Pleiotropic effects 
are likely because IL-22 is initially protective in inflammation, but induces tumorigenesis if 
uncontrolled during restitution of inflammation.55 Therefore, dysregulation of the IL-22/IL-22BP axis 
may play a pivotal role in IBD-CRC development, perhaps in the context of anti-TNF therapy. 
IL-21 is a multifunctional cytokine produced mainly by T-cell subsets such as follicular helper 
T-cells and Th17 cells. Some studies suggest IL-21 deficient mice are protected from DSS and 
trinitrobenzene sulfonic acid (TNBS)-induced colitis and this is likely because they are unable to 
upregulate Th17 responses.56 However, other studies have suggested that IL-21 signalling, through 
IL-21R, is protective in DSS-treated mice due to downregulation of Th1 and upregulation of Th2, 
Th17 and Treg responses.57 Studies have reported a reduced tumour burden in AOM/DSS-treated IL-
21-/- mice58 and the underlying mechanism may be due to reduced number of infiltrating T-cells, 




















Recent advances in the immunopathogenesis of IBD-CRC 
There remains a paucity of data characterising the immune cell landscape in human IBD-CRC. 
From the studies that exist, IBD-CRC has a lower number of immune cells expressing CD3, CD8, 
Foxp3 or PD-L1;59 increased CD3+ and CD8+ lymphocytes are associated with improved prognosis.59 
There is a need to comprehensively characterise the cells and cytokines that define the 
inflammation-dysplasia-carcinoma sequence.  
The role of macrophages in IBD-CRC is poorly defined. Macrophages and mast cells infiltrate 
the colonic submucosa in a stage-dependent manner in the progression from inflammation to 
dysplasia to cancer.60 Macrophage migration inhibitory factor (MIF) mediates macrophage and T-cell 
recruitment and MIF-/- mice treated with AOM/DSS have an increased tumour burden, associated 
with lower levels of macrophages.61 Fibrinogen-like protein 2 (Fgl2) may be important for 
macrophage recruitment +/- polarisation as Fgl2 loss induces M1-polarised and suppresses M2-
polarised macrophages; Fgl2 may therefore reduce inflammation and IBD-CRC.62 In contrast, TGFβ 
promotes macrophage recruitment through expression of CCR2 in the tumour microenvironment, 
and myeloid-cell TGFβ2 expression worsens AOM/DSS-induced tumorigenesis. Conditional TGFβ2 
knock-out mice have reduced IL-6 and TNF-ɑ expression, and increased numbers of Foxp3+ Tregs in 
the early stages of carcinogenesis.62 This suggests a pathogenic role of TGFβ signalling via 
macrophages in IBD-CRC. This hypothesis is strengthened by a study that reported conjugated 
linoleic acid ameliorated DSS-induced murine colitis through a macrophage PPARγ receptor-
dependent pathway, whereas PPARγ activation induced TGFβ production by macrophages and T-
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A novel subset of Foxp3+RORγt+ T-cells have been described and were thought to represent 
an intermediate stage during differentiation between immunosuppressive Tregs and 
proinflammatory Th17 cells. However, these cells can also be stable and functional (regulatory) in 
the intestine. Patients with IBD have increased expression of this unique T-cell subset, associated 
with IBD-dysplasia.64–66 A recent study using AOM/DSS-treated mice reported that Foxp3+RORγt+ T-
cells reduce the expression of FoxO3 in tumour infiltrating dendritic cells - FoxO3 is a transcription 
factor that controls the production of IL-6 by antigen presenting cells. This results in aberrant IL-6 
signalling that upregulates STAT3 and induces proliferation of dysplastic cells.66 
Barcode sequence analysis using 16S (MiSeq for bacteria) and ITS2 (pyrosequencing for 
fungi) reported a difference in bacterial, but not fungal, microbiome populations in IBD-CRC patients 
compared with both healthy controls and S-CRC.67 Compared with S-CRC, IBD-CRC patients have 
increased Enterobacteriaceae family and Sphingomonas genus and reduced Fusobacterium and 
Ruminococcus genus.67 The mechanistic, clinical and therapeutic consequences of microbial 
dysbiosis in IBD-CRC are poorly understood. Some bacteria, such as Bacteroides fragilis, are 
protective68,69 whereas others such as Streptococcus gallolyticus are pathogenic.70 Faecal microbial 
transplantation (FMT) is being trialled as a therapy for IBD, with variable success. Transplantation of 
carcinogenic bacteria may occur during FMT; robust screening and appropriate follow-up is needed 
to minimise FMT-associated IBD-CRC.71  
Antimicrobial peptides, such as cathelicidin/LL-37, are essential for maintaining intestinal 
homeostasis. It is unsurprising that AOM/DSS-treated cathelicidin-related antimicrobial peptide 
knock-out mice have an increased tumour burden.72 This field is in its infancy and further work is 
required to determine whether bacteria and/or defence peptides play a significant role in the 
development of IBD-CRC.  
Zhong and colleagues recently reviewed conflicting data on caspase recruitment domain-















  14 
 
 
role for CARD9 may be through IL-1β mediated STAT3 activation; however, whether CARD9 
contribution to inflammasome-mediated cytokine production and intestinal fungi promote or 
prevent IBD-CRC is undetermined.73  
The immunomodulatory role the appendix has also recently attracted interest, as 
appendicectomy has been shown to induce clinical improvement in UC.74 However, appendicectomy 
is also associated with increased risk of developing IBD-dysplasia and IBD-CRC.75 While trials are 
ongoing,76 mechanistic data elucidating the impact of appendicectomy on the gut microbiota and 
immune cell responses is currently lacking. 
 
 
IMMUNOSUPPRESSION CAN BE A DOUBLE-EDGED SWORD IN IBD-CRC 
The pro- or anti-tumour effects of 5-aminosalicylate, traditional immunomodulator (e.g. 
thiopurine) and anti-TNF therapy in IBD has been extensively discussed elsewhere.77–79 IBD Cancer 
and Serious Infection in Europe (I-CARE) is an ongoing prospective, longitudinal, observational, 
multicentre (n=16 countries) cohort study that aims to determine the risk of developing cancer or 
serious infections in IBD patients receiving immunosuppressive and biologic therapies 
(NCT02377258). Newly-identified signalling pathways that can be manipulated to ameliorate 
inflammation may have unintended carcinogenic effects. This section explores the potential pro- or 




















Therapeutic manipulation of the IL-12/IL-23 axis 
Ustekinumab is a humanised monoclonal antibody that binds to the p40 subunit that 
comprises both IL-12 and IL-23.80 The impact of p40 neutralisation on IBD-CRC development is 
mostly unknown; however, the impact of neutralising IL-12 and IL-23 activity can be considered 
separately. IL-12 induces anti-tumour immunity (involving IFN-γ, CD4+ and CD8+T-cells)81 whereas IL-
23 can promote carcinogenesis involving IL-17-associated pathways.52 Teng and colleagues 
investigated the impact of IL-23 and IL-12 on methylcholanthrene-induced p53 mutant cancers in 
murine models and reported that IL-23p19 inhibition reduced the malignant potential of colonic 
lesions whereas IL-12/23p40 inhibition enhanced tumour outgrowth.82 Therefore, neutralising p40 
may have some theoretical or potential pro-tumour effects in humans. A randomised control trial 
involving 961 patients with moderate-to-severe UC reported one case of colonic and one case of 
rectal cancer in patients receiving ustekinumab (n=825) over 52 weeks, compared with zero CRC in 
patients receiving placebo (n=319).83 An observational cohort study has started recruiting patients to 
assess the long-term safety of ustekinumab compared with other biologics in CD; the primary 
outcome is incidence of malignancy with a time frame of up to 12 years (NCT04372108). 
Targeted anti-IL-23 therapies are thus being explored for IBD as, theoretically, targeted IL-23 
blockade therapy may ameliorate inflammation and reduce the risk of IBD-CRC.84 Anti-IL-23 
therapies against the p19 subunit are being trialled for CD patients compared with ustekinumab, 
including risankizumab (NCT04524611), mirikizumab (NCT03926130) and guselkumab 
(NCT03466411). All trials have relatively short follow-up periods which limits their usefulness for 




















Therapies targeting leukocyte trafficking 
ɑ4β7 is an integrin (a transmembrane protein that facilitates cell adhesion) expressed on 
lymphocytes and is associated with increased responsiveness to pro-inflammatory cytokines IL-6, IL-
7 and IL-21.85 ɑ4β7 allows peripheral lymphocytes to bind with mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) on intestinal endothelial cells, which allows lymphocytes to undergo 
diapedesis into the lamina propria.  
Vedolizumab is the first humanised, gut-selective antibody used to treat IBD that blocks 
ɑ4β7 integrin-expressing lymphocytes from trafficking from the systemic circulation into the lamina 
propria.86 Data generally supports no increased risk of malignancy in patients receiving vedolizumab: 
a retrospective analysis of 1087 patients reported only one case of IBD-CRC.87 However, median 
follow up in this study was only 302 days which is too short to determine the true risk of 
malignancy.87 These findings are supported by other data, such as a study that reports four CRC 
cases in a population of >2800 patients, which translates to 0.1/100 person years, and is no different 
to the background IBD risk (2.1/1000 person years, 95% CI 1.3, 3.2).88 A recent retrospective cohort 
study reported no increased risk of new or recurrent cancer among patients with IBD and a history 
of cancer who were treated with vedolizumab or anti-TNF therapy, compared with patients who did 
not receive immunosuppression (follow-up median 6.2 person years).89 Caution may be warranted, 
especially in patients with concurrent PSC. A retrospective observational cohort study (median 
follow-up of 19 months) reported that, of 75 patients with IBD and PSC treated with vedolizumab, 9 
patients developed digestive neoplasia - seven of which were colorectal cancers.90 While there are 
no published data for similar therapies, there is an ongoing large interventional trial investigating 















  17 
 
 
Preliminary data suggest MAdCAM antibodies are efficacious in IBD, especially UC.91 No 
studies have assessed the impact of MAdCAM antibodies on IBD-CRC development; however, 
MAdCAM-1 expression is reduced in colonic adenocarcinomas.92 This could suggest that blocking 
MAdCAM may be advantageous for tumour development warranting further investigation. There is 
an ongoing safety extension study investigating ontamalimab (MAdCAM-1 inhibitor) for the 
treatment of moderate to severe IBD (NCT03283085). 
 
Small molecule therapies 
Compared with monoclonal antibodies, small molecules are attractive as they have no 
inherent immunogenicity (they are synthetic drugs rather than proteins), can be administered orally 
and have relatively stable and predictable pharmacokinetics. Small molecules include Janus Kinase 
(JAK) inhibitors, tyrosine kinase inhibitors and Sphingosine-1-Phosphate (S1P) receptor antagonists. 
Cytokines principally impact immune cell function by signalling through JAK/STAT pathways. 
As previously discussed, targeting these pathways could theoretically improve colitis and reduce risk 
of IBD-CRC. With JAK-inhibitors, the extent of signal inhibition is related to the target of the small 
molecule (i.e. pan- versus selective- JAK inhibition). Most data relate to tofacitinib: data from 1157 
patients who received tofacitinib (JAK3-specific inhibitor, with lesser activity against JAK1/ JAK2) 
reported that 11 patients developed malignancy (excluding non-melanoma skin cancer), one of 
which was colorectal adenocarcinoma – the risk of malignancy was not significant (IR 0.7 95%CI 0.3, 
1.2).93 However, we must be cautious as these data are only over 4.4 years. Another study reported 
that 2/1124 patients receiving tofacitinib developed CRC (IR 0.08 95%CI 0.01, 0.27), with evaluation 
up to 6.8 years; however, one cancer possibly developed prior to tofacitinib therapy.94 Data from 
other JAK-inhibitors are on the horizon for IBD, such as TD-1473 (NCT03920254), filgotinib 
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Tyrosine kinase inhibitors may also be therapeutic in IBD and deucravacitinib (BMS-986165) is an 
allosteric inhibitor of tyrosine kinase 2 under investigation for CD (NCT03599622) and UC 
(NCT03934216, NCT04613518). Long-term follow-up studies using these patient cohorts will be 
important to determine IBD-CRC risk. 
Sphingolipids are ubiquitous bioactive molecules that form part of the cell membrane and 
play a role in a multitude of cell functions such as migration, proliferation and apoptosis. S1P is the 
final product derived from sphingolipids and can activate STAT3 and NF-𝛋B. STAT3-induced S1P 
receptor expression is important for persistent STAT3 activation (creating a positive feedback loop in 
immune and tumour cells) during carcinogenesis.95 S1P also has immunoregulatory activity as T-cells 
require S1P signalling to egress from the thymus and from peripheral lymphoid organs.96 A pro-
tumour role for S1P, and it’s regulatory enzyme sphingosine-kinase 1 (SphK1), has therefore been 
hypothesised. In a small (n=20 patients) translational study, biopsies from curative surgical 
resections reported higher expression of phosphorylated SphK1 in IBD-CRC compared with S-CRC, 
which suggests the S1P pathway is especially important for IBD-related malignancy.97 Given the 
outlined mechanism of action, inhibiting S1P may reduce both IBD and IBD-CRC. Carcinogenesis may 
be triggered by S1P lyase1 (SGPL1), which is responsible for the irreversible degradation of S1P. In an 
AOM/DSS model that utilised isogenic bone marrow transplantation of inducible SGPL1 knockout 
mice, immune-cell SGPL1 knockout was associated with colitis and pathological crypt remodelling 
with extracellular S1P signalling which caused delayed tumour formation. However, tissue-SGPL1 
knockout reduced immune activity and induced immediate tumorigenesis which was associated with 
an IL-12 to IL-23 shift.98 This suggests that understanding the difference between tissue vs. immune 
cell S1P lyase activity is important for optimising S1P blockade therapy to treat IBD and reduce IBD-
CRC risk. There are ongoing safety and efficacy trials for the S1P receptor modulators, such as 
etrasimod (NCT03950232) and ozanimod (NCT0253112). 



















Patients with IBD have increased risk for developing CRC. The inflammation-dysplasia-
carcinoma sequence of IBD-CRC is distinct from the sporadic normal-adenoma-adenocarcinoma 
sequence and confers a poorer prognosis. While key inflammatory pathways have been described, 
the immune cell landscape of IBD-CRC remains poorly characterised, although new data suggest 
Th17 cells and macrophages play important roles. 
The selection pressure exerted by efficacious therapeutic agents is unknown and, although 
the overall inflammatory burden is lessened, the potential disruption to immune cancer surveillance 
is yet to be fully appreciated. Indeed, it will be some time before we see the full effect of these 
therapies on the incidence of IBD-CRC. More sensitive tools to detect early dysplasia are needed, 
and may include non-invasive stool testing for DNA methylation markers and improved computer-
aided identification of dysplasia during surveillance procedures.99  
In the clinic, preventing the burden of inflammation is likely the most important factor for 
minimising IBD-CRC. With the growing therapeutic arsenal, caution is warranted that 
immunosuppression can be a double-edged sword, and it will be some time before we see the full 
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FIGURE LEGENEDS:  
Table 1 – IBD-CRC is distinct from S-CRC. This table illustrates the key epidemiological, 
pathophysiological and clinical differences between sporadic (S-CRC) and inflammatory bowel 
disease associated colorectal cancer (IBD-CRC).  
 
 
Figure 1 – Clinical photographs and photomicrographs of IBD-CRC. Endoscopic images and 
histopathology photomicrographs illustrate the development of inflammatory bowel disease- 
associated colorectal cancer (IBD-CRC) through the ‘inflammation-dysplasia-carcinoma’ sequence. 
Histopathology photomicrographs provided by Lothian NRS Bioresource (MJA) and colonoscopy 
images provided by Edinburgh IBD Unit (SD).  
 
Figure 2 –Contemporary Model for the Molecular Pathogenesis of A) Sporadic and B) IBD-
associated Colorectal Cancer. Sporadic colorectal cancer (S-CRC) develops through the ‘adenoma-
dysplasia-carcinoma sequence’ whereas inflammatory bowel disease-associated colorectal cancer 
develops through the ‘inflammation-dysplasia-carcinoma’ sequence. The figure illustrates genetic 
mutations that can contribute to cancer development. 
 
Figure 3 - Immunopathogenesis of IBD-CRC –a perfect storm? There is dysregulation of critical 
immune-mediated pathways in IBD-CRC, such as NF𝛋B and IL-6/STAT3 signalling, and Th17 cell 
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Table 1 – IBD-CRC is distinct from S-CRC.  
 S-CRC IBD-CRC 
Epidemiology 
Disease Burden 10% of global cancer 
diagnoses.100 
IBD patients have a  higher 
incidence of CRC, possibly 
>60%.4,7,101 
Sex Male preponderance.100,102 Male preponderance.3 
Age Older age of onset (>50s); an 
increasing incidence in 
younger patients.102 
Younger age of IBD onset.3 
Paediatric IBD-CRCs can 
develop.8 Patients with IBD 
are living longer.1 
Risk Factors Diet, smoking, obesity, family 
CRC history, H.pylori, alcohol 
(J-shaped association likely), 
colonic polyps and others. 103–
106 
Extensive colitis, increased 
duration of disease, family 
history of S-CRC, PSC.107–109 
Disease Pathogenesis 
Pre-malignant lesion Adenomatous polyps 
(polypoid/sessile).110 
Flat dysplasia. Genetic 
aberrations seen (TP53 
mutations) in histologically 
normal mucosa.11,14,17 
Molecular Sequence Mostly adenoma-carcinoma 
sequence (slow).110 
Inflammation-dysplasia-
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Genetic Aberrations Chromosomal instability, 
microsatellite instability and 
CpG island methylator 
phenotype (CIMP) pathways 
(not mutually exclusive). Early 
and more frequent APC 
mutations. Late and frequent 
TP53 mutations.14,15,111,112  
Mutation sequence is 
‘reversed’: early TP53 
mutation, late and 
infrequent loss of APC, 




Regeneration to the 
Initiation of Cancer 
Promotes cancer 
progression.113 
Drives mutagenesis and 
selects for mutagenic 
clones.11–13 
Contribution of 
Inflammation to the 
Progression to cancer 
Tumour-promoting 
inflammation is critical for 
most cancers, including 
colorectal cancer.113 
Critical pathways signal 
through NF-𝛋B and IL-
6/STAT3.26,27,38–40,42,46,114,28–
32,35–37 Th17 cells and 




Endoscopic Characteristics Commonly raised/ polypoidal 
lesions; some sessile. 
Flat dysplasia. Synchronous 
& recurrent tumours.  



















differentiation; fewer contain 
mucinous/signet ring cell 
morphology.116 
Mucinous/ signet ring cell 
differentiation is more 
common.10,116 
Mortality and Prognosis Prognosis is improving, 
especially if diagnosed early.102 
Poor prognosis compared 
with S-CRC (2-fold).117 
Increase in recurrence (3-
fold).10 Poor prognosis 
associated with PSC, male 
sex, extensive colitis and 
early age of 
diagnosis.4,7,9,10,107,108,118  
Abbreviations: APC (adenomatous polyposis coli); IBD-CRC (Inflammatory Bowel Disease-associated 
colorectal cancer); IL-6 (interleukin-6); KRAS (Kirsten rat sarcoma viral oncogene homolog); MSI 
(microsatellite instability); NF-𝛋B (nuclear factor kappa-light-chain-enhancer of activated B cells); 
PSC (primary sclerosing cholangitis); qFIT (quantitative Faecal Immunohistochemical Test); S-CRC 
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